# Thalidomide in Treating Patients With Myelofibrosis

> **NCT00015821** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 43 (estimated)

## Conditions studied

- Primary Myelofibrosis

## Interventions

- **DRUG:** thalidomide
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00015821
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-05
- **Primary completion:** 2007-12
- **Final completion:** —
- **Target enrollment:** 43 (ESTIMATED)
- **Last updated:** 2013-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00015821

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00015821, "Thalidomide in Treating Patients With Myelofibrosis". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00015821. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*